Imanova Limited will be supporting the MRC UK Dementia Research Platform (UKDP) by providing their expertise in clinical imaging in a major new study of biomarkers for Alzheimer’s disease.
Led by Professor Simon Lovestone of King’s College London and Oxford University and using Imanova’s acknowledged expertise in novel tracers, imaging and analysis, the research will identify biomarkers for Alzheimer’s disease in pre-clinical patients. This will in turn enable early intervention, increasingly believed to be the key to successful treatment outcomes.
Kevin Cox, CEO at Imanova Limited, outlined the value of combining Imanova’s expertise within novel research concepts.
“As the use of imaging biomarkers grows, we hope to collaborate in more studies like these providing our expertise to augment understanding and visualise research.” stated Cox, “Being named as a full collaborator is a huge achievement for Imanova and it is encouraging to see that the UKDP will incorporate partnerships with pharmaceutical companies, SMEs and academia as a means to improve treatment and care in dementias.”
If successful, this initial study will lead into a larger programme within the UKDP.